



Attorney Docket No.: 6599.200-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Kodra et al.

Serial No.: 10/735,986

Group Art Unit: To be assigned

Filed: December 15, 2003

Examiner: To be assigned

For: Novel Glucagon Antagonists

CERTIFICATE OF MAILING UNDER 37 CFR 1.8(a)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

I hereby certify that the attached correspondence comprising:

1. Information Disclosure Statement
2. Form PTO-1449
3. Copy of References (30)

is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

on **March 29, 2004**

Dolly Kapadia
(name of person mailing paper)

Dolly Kapadia
(signature of person mailing paper)

Attorney Docket No.: 6599.200-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Kodra et al.

Application No.: 10/735,986

Group Art Unit: To be assigned

Filed: December 15, 2003

Examiner: To be assigned

For: Novel Glucagon Antagonists

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants submit herewith references which they believe may be material to the patentability of this application and with respect to which there may be a duty to disclose in accordance with 37 C.F.R. 1.56.

While the references may be "material" under 37 C.F.R. 1.56, it is not intended to constitute an admission that the references are "prior art" unless specifically designated as such.

The filing of this Information Disclosure Statement shall not be construed as a representation that no material references other than those listed exist or that a search has been conducted.

The references are listed in Form PTO-1449 which is in accordance with the requirements of M.P.E.P. 609. A copy of the references is also enclosed.

The references are as follows:


1. U.S. Patent No. 4,359,474
2. U.S. Patent No. 4,374,130
3. U.S. Patent No. 5,776,954
4. U.S. Patent No. 5,837,719
5. U.S. Patent No. 5,880,139
6. WO 94/14426 A1
7. WO 97/16442 A1
8. WO 98/04528 A2
9. WO 98/21957 A1
10. WO 98/22108 A1
11. WO 98/22109 A1
12. WO 98/24780 A2 & A3
13. WO 98/24782 A2
14. WO 99/01423 A1
15. WO 99/24404 A1
16. WO 99/32448 A1
17. WO 00/39088 A1
18. WO 00/69810 A1
19. WO 02/06112 A1
20. WO 02/40444 A1
21. WO 02/40445 A1
22. WO 02/40446 A1
23. WO 03/064404 A1
24. Azizh et al., Bioorganic & Medicinal Chemistry Letters, Vol. 5, No. 16, pages 1849-1852 (1995)
25. Collins et al., Bioorganic & Medicinal Chemistry Letters, Vol. 2, No. 9, pages 915-918 (1992)
26. Handlon et al., American Chemical Society, Division of Medicinal Chemistry, Abstracts #164, 226th ACS National Meeting, Sept. 7-11, 2003
27. Madsen et al., J. Med. Chem., Vol. 41, pages 5150-5157 (1998)
28. Post et al., Proc. Natl. Acad. Sci. USA, Vol. 90, pages 1662-1666 (1993)
29. Unson et al., Peptides, Vol. 10, pages 1171-1177 (1989)
30. Unson et al., The Journal of Biological Chemistry, Vol. 269, No. 17, pages 12548-12551 (1994)

It is respectfully requested that these references be considered by the Patent and Trademark Office in its examination of the above-identified application and be made of record therein. The Examiner is also invited to contact the undersigned if there are any questions concerning this paper or the attached references.

The information disclosure statement submitted herewith is being filed **within** three months of the filing date of a national application or date of entry into the national stage of an international application or **before** the mailing date of a first Office action on the merits, or **before** the mailing date of a first Office action after the filing of a request for continued examination. Therefore, no fee is due. However, please charge any fees should they be required, to Novo Nordisk Pharmaceuticals, Inc. Deposit Account No. 14-1447.

Date: March 29, 2004

Respectfully submitted,



Rosemarie R. Wilk-Orescan, Reg. No. 45,220
Novo Nordisk Pharmaceuticals, Inc.
100 College Road West
Princeton, NJ 08540
(609) 987-5800

Use the following customer number for all correspondence regarding this application.

23650

PATENT TRADEMARK OFFICE

FORM PTO-1449
(REV. 2-32)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

Atty. Docket No. 6599.200-US

Serial No. 10/735,986

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)

Applicant Kodra et al.

Filing Date December 15, 2003

Group To be assigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	4,359,474	11/16/82	Anderson et al.	424	273	
	4,374,130	2/15/83	Barcza	424	184	
	5,776,954	7/7/98	De Laszlo et al.	514	340	
	5,837,719	11/17/98	De Laszlo et al.	514	343	
	5,880,139	3/9/99	Chang	514	326	

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	WO 94/14426 A1	7/7/94	PCT				
	WO 97/16442 A1	5/9/97	PCT				
	WO 98/04528 A2	2/5/98	PCT				
	WO 98/21957 A1	5/28/98	PCT				
	WO 98/22108 A1	5/28/98	PCT				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Azizeh et al., Bioorganic & Medicinal Chemistry Letters, Vol. 5, No. 16, pages 1849-1852 (1995)
	Collins et al., Bioorganic & Medicinal Chemistry Letters, Vol. 2, No. 9, pages 915-918 (1992)
	Handlon et al., American Chemical Society, Division of Medicinal Chemistry, Abstracts #164, 226 th ACS National Meeting, Sept. 7-11, 2003
	Madsen et al., J. Med. Chem., Vol. 41, pages 5150-5157 (1998)
	Post et al., Proc. Natl. Acad. Sci. USA, Vol. 90, pages 1662-1666 (1993)
	Unson et al., Peptides, Vol. 10, pages 1171-1177 (1989)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

FORM PTO-1449
(Rev. 2-32)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

Atty. Docket No. 6599.200-US

Serial No. 10/735,986

INFORMATION DISCLOSURE
STATEMENT BY APPLICANTApplicant **Kodra et al.**

(Use several sheets if necessary)

Filing Date **December 15, 2003**Group **To be assigned**

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	WO 99/32448 A1	7/1/99	PCT				
	WO 00/39088 A1	7/6/00	PCT				
	WO 00/69810 A1	11/23/00	PCT				
	WO 02/06112 A1	1/24/02	PCT				
	WO 02/40444 A1	5/23/02	PCT				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449
(Rev. 2-32)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

Atty. Docket No. 6599.200-US

Serial No. 10/735,986

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)

Applicant Kodra et al.

Filing Date December 15, 2003

Group To be assigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	WO 02/40445 A1	5/23/02	PCT				
	WO 02/40446 A1	5/23/02	PCT				
	WO 03/064404 A1	8/7/03	PCT				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.